Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologyDiseaseBasal Cell CarcinomaSubgroupICD10C44.-MeSHCarcinoma, Basal CellSequenceChemotherapyChemo-substanceCemiplimabVismodegibChemo-substanceCemiplimabVismodegibChemo-substanceCemiplimabVismodegibChemo-substanceCemiplimabVismodegibNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionSupportive substanceBalanced Crystalloid SolutionNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseTherapy intentionpalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlArthalgiaColitisConstipationDiarrheaEmetogenicity (ASCO)HepatotoxicityHyperkeratosisHypertensionHypokalemiaHypophysitisHypothyroidismInfectionsMyalgiasNauseaPneumonitisPruritusRenal Failure only studiesPublicationAuthorSekulic AStratigos AJDiseasefortgeschrittenes oder metastasiertes Basalzellkarzinom nach Hedgehog Inhibitor-Therapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes BasalzellkarzinomOriginAndreas Syggros Hospital - National and Kapodistrian University of Athens, Athens, GreeceMayo Clinic Scottsdale, USA, ERIVANCE BCC studyProtocols in Revision 2 protocols foundProtocols under revision.Cemiplimab 350, Basal Cell Carcinoma (PID1867 V1.0)Vismodegib 150, Basal Cell Carcinoma (PID1858 V1.0)
